The Business Research Company’s report on the Hepatorenal Syndrome Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
How are market drivers shaping the future growth trajectory of the hepatorenal syndrome industry?
The rising prevalence of liver diseases is expected to propel the growth of the hepatorenal syndrome market going forward. Liver diseases refer to conditions that impair liver function, including hepatitis, cirrhosis, fatty liver, liver cancer, genetic disorders, and autoimmune diseases. The increase in liver diseases is due to obesity, diabetes, alcohol use, viral infections, poor diet, and toxin exposure. The rising prevalence of liver diseases, such as cirrhosis and acute liver failure, increases the risk of hepatorenal syndrome (HRS) by causing severe hemodynamic and kidney dysfunction due to progressive liver impairment. For instance, in April 2024, according to the Office for Health Improvement & Disparities (OHID), a UK-based government department, reported that UK hospital admissions for liver disease rose to 155.2 per 100,000 in 2023, up from 150.6 per 100,000 in 2022. Therefore, the rising prevalence of liver diseases is driving the growth of the hepatorenal syndrome market.
Increase In Research And Development Investments Driving The Growth Of The Market Due To Advancements In Therapies And Diagnostics
The increase in research and development investments is expected to propel the growth of the hepatorenal syndrome market going forward. Research and development investments refer to funding allocated for innovation, product improvement, and new technology development. The rise in research and development investments is driven by technological advancements, competition, healthcare needs, and demand for innovation. Research and development investments in hepatorenal syndrome drive advancements in innovative therapies, diagnostic tools, and treatment approaches, improving patient outcomes and survival rates. For instance, in April 2024, according to the Office for National Statistics, a UK-based government department, a 10.5% rise in government R&D spending was reported, reaching £15.5 billion (USD 16.18 billion) in 2022, up from £14.0 billion (USD 14.61 billion) in 2021. Therefore, the increase in research and development investments is driving the growth of the hepatorenal syndrome market.
Access Your Free Sample of the Global Hepatorenal Syndrome Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=22001&type=smp
What is the estimated market size of the hepatorenal syndrome sector by 2029, based on current forecasts?
The hepatorenal syndrome market size has grown strongly in recent years. It will grow from $1.29 billion in 2024 to $1.38 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to increasing healthcare expenditure, a rise in hepatitis infections, a rise in government-driven initiatives, a rising incidence of virally infected liver diseases, and an increase in research and development investments.
The hepatorenal syndrome market size is expected to see strong growth in the next few years. It will grow to $1.83 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to the rising prevalence of liver diseases, the rise in liver transplant programs, increasing disease prevalence, increasing cases of direct kidney injury, and the increase in the incidence of liver diseases. Major trends in the forecast period include advanced technologies, supportive government programs, improved diagnostic tools, advancements in personalized medicine, and advancements in the field of nephrology.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=22001&type=smp
Who are the top players in the hepatorenal syndrome market?
Major companies operating in the hepatorenal syndrome market are Eli Lilly and Company, Becton Dickinson and Company, Teva Pharmaceutical Industries Ltd, Baxter International Inc., Ferring Pharmaceuticals Ltd, Mallinckrodt Pharmaceuticals, Zentiva k.s, Hybio Pharmaceutical Co. Ltd, Cumberland Pharmaceuticals Inc., La Jolla Pharmaceutical Company, Innoviva Specialty Therapeutics Inc, SeaStar Medical, New Medicon Pharma Lab, Orphan Therapeutics LLC, BioVie Inc., Noorik Biopharmaceuticals, Ocelot Bio Inc., Ikaria Inc, PharmaIN Corp, ESP Pharma Inc.
What are the major trends in the hepatorenal syndrome market?
Major companies operating in the hepatorenal syndrome market are focusing on developing innovative devices, such as cytopheretic devices, to improve patient outcomes by reducing inflammation, stabilizing kidney function, and enhancing treatment effectiveness for Hepatorenal Syndrome (HRS). The cytopheretic device (Cytosorb) is an extracorporeal blood purification therapy designed to reduce systemic inflammation and immune activation in critically ill patients, including those with Hepatorenal Syndrome (HRS). For instance, in October 2023, SeaStar Medical Holding Corporation, a US-based medical device company, received FDA approval for its Selective Cytopheretic Device (SCD) for the treatment of hepatorenal syndrome (HRS). This advanced, cell-directed therapy targets hyperinflammation, a key driver of kidney dysfunction in patients with acute-on-chronic liver failure. By leveraging immunomodulation, SCD helps regulate abnormal immune responses, potentially supporting kidney recovery and improving patients’ eligibility for life-saving liver transplants. Its effectiveness in enhancing solid organ function has been demonstrated in preclinical and clinical studies across conditions such as sepsis, acute kidney injury (AKI), and cardiorenal syndrome.
Which geography holds the highest hepatorenal syndrome market share?
North America was the largest region in the hepatorenal syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hepatorenal syndrome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/hepatorenal-syndrome-global-market-report
How do different segments contribute to the overall expansion of the hepatorenal syndrome market?
The hepatorenal syndrome market covered in this report is segmented –
1) By Type: Type 1 Hepatorenal Syndrome, Type 2 Hepatorenal Syndrome, Other Types
2) By Treatment: Liver Transplantation, Terlipressin Infusion, Albumin Infusion, Hemodialysis, Vasoconstrictors, Antibiotic Therapy
3) By Diagnosis: Complete Blood Cell Count, Liver Function Tests, Urinalysis And Urine Electrolytes, Other Diagnosis
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels
5) By End Users: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Type 1 Hepatorenal Syndrome: Acute Kidney Injury-Associated HRS, Rapidly Progressive Renal Failure
2) By Type 2 Hepatorenal Syndrome: Chronic Kidney Dysfunction-Associated HRS, Slowly Progressive Renal Failure
3) By Other Types: HRS With Cirrhosis, HRS With Acute Liver Failure, HRS With Alcoholic Hepatitis
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22001
What defines the structure and scope of the hepatorenal syndrome market?
Hepatorenal Syndrome (HRS) is a severe complication of advanced liver disease, characterized by functional kidney failure due to reduced renal blood flow without structural kidney damage. It is caused by splanchnic vasodilation, leading to renal vasoconstriction and decreased glomerular filtration.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
